Table 8 Comparison of FSFI scores according to disease characteristics
From: Sexual function and chemotherapy in postmenopausal women with breast cancer
Item | Post-diagnosis | Post-chemotherapy | Reduction (%) | p* |
|---|---|---|---|---|
Median (IQR) | Median (IQR) | |||
Clinical stage | ||||
II A–B (n=8) | 14.8 (14.5 – 19.0) | 9.8 (7.2 – 12.1) | 33.8 | 0.012 |
III A–B (n=16) | 8.5 (2.6 – 16.4) | 2 (2 – 8) | 76.5 | 0.002 |
p† | 0.052 | 0.016 | ||
Tumor size | ||||
T2 (n=8) | 14.8 (14.5 – 19.0) | 9.8 (7.2 – 12.1) | 33.8 | 0.012 |
T3 (n=6) | 10.5 (6.6 – 18.2) | 4.6 (2.0 – 9.1) | 56.2 | 0.028 |
T4 (n=10) | 8.5 (2 – 15.6) | 2 (2 – 8) | 76.5 | 0.028 |
p† | 0.301 | 0.132 | ||
Receptor / HER2/neu status | ||||
ER+/PR+/HER2+ (n=1) | 8.8 (8.8 – 8.8) | 8 (8 – 8) | 9.1 | - |
ER+/PR–/ HER2+ (n=0) | - | - | - | - |
ER+/PR+/HER2– (n=9) | 12.8 (5.0 – 14.8) | 7.2 (2 – 9.6) | 43.8 | 0.018 |
ER+/PR–/HER2– (n=4) | 18.5 (8 – 20.8) | 6.0 (2 – 11.8) | 67.6 | 0.068 |
ER–/PR+/HER2+ (n=0) | - | - | - | - |
ER–/PR–/HER2+ (n=2) | 11.4 (2 – 20.7) | 2 (2 – 2) | 82.5 | 0.317 |
ER–/PR+/HER2– (n=0) | - | - | - | - |
ER–/PR–/HER2– (n=8) | 13.5 (5.0 – 18.7) | 5 (2 – 9.7) | 63.0 | 0.018 |
p‡ | 0.688 | 0.677 | ||
Histologic grade | ||||
Grade I (n=1) | 15 (15 – 15) | 7.2 (7.2 – 7.2) | 52.0 | - |
Grade II (n=17) | 14.5 (7.6 – 18.5) | 7.2 (2 – 10.6) | 50.3 | 0.001 |
Grade III (n=6) | 6.5 (2 – 15.8) | 2 (2 – 8.4) | 69.2 | 0.068 |
p‡ | 0.362 | 0.489 | ||
Prior diagnosis | ||||
No (n=19) | 14.5 (4.2 – 17.6) | 7.2 (2 – 9.9) | 50.3 | 0.001 |
Yes (n=5) | 8.8 (7.7 – 17.1) | 2 (2 – 8) | 77.3 | 0.043 |
p† | 0.406 | 0.891 |